Immunization, Hib3 in Poland
Poland: Immunization, Hib3 was 94.0% in 2024. ▲ Rising
Immunization, Hib3 in Poland, 2005–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
In 2024, immunization, hib3 in Poland stood at 94.0%.
That represents a change of down 4.1% over ten years.
Over the whole period, immunization, hib3 in Poland peaked at 99.0% in 2009 and was at its lowest, 22.0%, in 2005.
That places Poland 64th out of 191 countries with data for 2024, putting it in the middle of the range.
The long-run direction has been consistently rising across the 20 years of available data.
Immunization, Hib3 in Poland, year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 2005 | 22.0% | — |
| 2006 | 31.0% | +40.9% |
| 2007 | 88.0% | +183.9% |
| 2008 | 98.0% | +11.4% |
| 2009 | 99.0% | +1.0% |
| 2010 | 99.0% | +0.0% |
| 2011 | 99.0% | +0.0% |
| 2012 | 99.0% | +0.0% |
| 2013 | 99.0% | +0.0% |
| 2014 | 98.0% | -1.0% |
| 2015 | 98.0% | +0.0% |
| 2016 | 98.0% | +0.0% |
| 2017 | 96.0% | -2.0% |
| 2018 | 95.0% | -1.0% |
| 2019 | 95.0% | +0.0% |
| 2020 | 94.0% | -1.1% |
| 2021 | 94.0% | +0.0% |
| 2022 | 94.0% | +0.0% |
| 2023 | 94.0% | +0.0% |
| 2024 | 94.0% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 67.6% | 22.0% | 99.0% | 5 |
| 2010s | 97.6% | 95.0% | 99.0% | 10 |
| 2020s | 94.0% | 94.0% | 94.0% | 5 |
Countries ranked near Poland
- 64 Armenia 94.0% compare
- 64 Barbados 94.0% compare
- 64 Botswana 94.0% compare
- 64 Bulgaria 94.0% compare
- 64 Cyprus 94.0% compare
- 64 Fiji 94.0% compare
- 64 Iceland 94.0% compare
- 64 India 94.0% compare
- 64 Kiribati 94.0% compare
- 64 Seychelles 94.0% compare
- 64 Spain 94.0% compare
- 64 Tuvalu 94.0% compare
- 64 Uruguay 94.0% compare
More health data for Poland
- Un projection of annual infant deaths, annual growth rate -1.23 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.9071 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,693 deaths per 1,000 people (2090)
- Number of infants who die before age 1 80 deaths (2100)
- Population ages 05-09, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 05-09, female, per capita 0.0244 units per person (2025)
- Population ages 05-09, male, annual growth rate -1.1 % change on previous year (2025)
- Population ages 05-09, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 05-09, male, per capita 0.0258 units per person (2025)
- Population ages 10-14, female, annual growth rate -1.79 % change on previous year (2025)
Frequently asked questions
- What is immunization, hib3 in Poland?
- Immunization, hib3 in Poland was 94.0% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in Poland?
- The highest recorded value was 99.0% in 2009.
- What is the lowest immunization, hib3 recorded in Poland?
- The lowest recorded value was 22.0% in 2005.
- How does Poland rank for immunization, hib3?
- Poland ranks 64th out of 191 countries with data for 2024.
- Is immunization, hib3 rising or falling in Poland?
- Over the last ten years it is down 4.1%. The long-run trend across the full record is rising.
- Where does this Poland data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 20 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.